• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail
-

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.

Links

Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Show All Studies
Export to ExcelExport to Excel
General
Application Number P070027 S011
Most Recent Protocol Version Approved 07/16/2014
Study Name Registry
Study Status Progress Adequate
General Study Protocol Parameters
Study Design Prospective Cohort Study
Study involve follow-up of premarket cohort (Y/N) No
Data Source New Data Collection
Comparison Group Objective Performance Criterion
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description Multi-center, prospective, non-randomized, single arm post-market surveillance clinical registry study.

  show the rest ...
Study Population Description Patients of 18 years of age and older who require secondary endovascular intervention for the   show the rest ...
Sample Size 20
Data Collection Endovascular treatment success, failure mode, adverse events, AAA-related mortality, all cause mortality, conversions to open   show the rest ...
Followup Visits and Length of Followup No specified - to be determined by standard of care. 5 years.


Registry Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Reporting Status
6 month report 08/05/2010 08/02/2010 On Time
1 year report 02/04/2011 02/03/2011 On Time
18 month report 08/05/2011 08/03/2011 On Time
2 year report 02/04/2012 02/02/2012 On Time
3 year report 02/03/2013 01/31/2013 On Time
4 year report 02/03/2014 01/31/2014 On Time
5 year report 02/03/2015    
6 year report 02/03/2016    

Show All Studies

-
-